Panobinostat

Bezeichnung:Panobinostat

CAS-Nr404950-80-7

Englisch Name:Panobinostat

CBNumberCB61009161

SummenformelC21H23N3O2

Molgewicht349.43

MOL-Datei404950-80-7.mol

Panobinostat physikalisch-chemischer Eigenschaften

Schmelzpunkt	114-117?C
Dichte	1.241±0.06 g/cm3(Predicted)
storage temp.	-20°C Freezer, Under Inert Atmosphere
Löslichkeit	Soluble in DMSO (up to 100 mg/ml) or in Ethanol (up to 5 mg/ml with warming).
Aggregatzustand	solid
pka	8.71±0.23(Predicted)
Farbe	Off-white
Stabilität	Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month.

Sicherheit

R-Sätze:	22-36/37/38-20
S-Sätze:	24/25
HS Code	29339900

Gefahreninformationscode (GHS)

Panobinostat Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Panobinostat is a potent inhibitor of all histone deacetylases (HDACs), with K_i values ranging from 0.6 to 31 nM for HDAC1-11. Through this action, it leads to acetylation of a range of cellular proteins, resulting in cell cycle arrest and apoptosis in cancer cells. It has potential applications in several different forms of cancer as well as in spinal muscular atrophy and HIV therapy.
Chemische Eigenschaften
Yellow Solid
Verwenden
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.
Verwenden
The novel labelled histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.
Definition
ChEBI: A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its la tate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.
Clinical Use
Histone deacetylase (HDAC) inhibitor:
Treatment of relapsed and/or refractory multiple myeloma
target
HDAC (MOLT-4 cells)
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Analgesics: avoid with dextromethorphan possibly increased risk of ventricular arrhythmias with methadone - avoid.
Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone and possibly disopyramide - avoid.
Antibacterials: increased risk of ventricular arrhythmias with clarithromycin and moxifloxacin - avoid; avoid with rifampicin.
Antidepressants: avoid with St John’s wort.
Antiepileptics: avoid with carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
Antifungals: concentration increased by ketoconazole and possibly posaconazole and voriconazole - reduce panobinostat dose; concentration possibly increased by itraconazole - avoid.
Antimalarials: possibly increased risk of ventricular arrhythmias with chloroquine - avoid.
Antipsychotics: avoid with pimozide.
Antivirals: concentration possibly increased by ritonavir and saquinavir - reduce dose of panobinostat.
Beta-blockers: possibly increased risk of ventricular arrhythmias with sotalol - avoid.
Grapefruit juice: avoid concomitant use.
5HT3 antagonists: possibly increased risk of ventricular arrhythmias with granisetron and ondansetron - avoid with granisetron.
Stoffwechsel
Panobinostat is extensively metabolised, and a large fraction of the dose is metabolised before reaching the systemic circulation by reduction, hydrolysis, oxidation and glucuronidation. Oxidative metabolism of panobinostat played a less prominent role, with approximately 40% of the dose eliminated by this pathway. Cytochrome P450 3A4 (CYP3A4) is the main oxidation enzyme, with potential minor involvement of CYP2D6 and 2C19.
Panobinostat represented 6-9% of the drug-related exposure in plasma. The parent substance is deemed to be responsible for the overall pharmacological activity of panobinostat.
After a single oral dose of [14C]-panobinostat in patients, 29-51% of administered radioactivity is excreted in the urine and 44-77% in the faeces. Unchanged panobinostat accounted for <2.5% of the dose in urine and <3.5% of the dose in faeces.
Lager
Store at -20°C
Einzelnachweise
1) Geng et al. (2006), Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer; Cancer Res., 66 11298 2) George et al. (2005), Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3; Blood, 105 1768 3) Maiso et al. (2006), The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance; Cancer Res., 66 5781

Panobinostat Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy